ETANERCEPT, ADALIMUMAB AND METHOTREXATE UTILIZATION BY JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AND THE OCCURRENCE OF UVEITIS

被引：0
作者：
Roshak, K. [1 ]
Sopczynski, J. M. [2 ]
Suehiro, R. M. [3 ]
Marshall, L. [3 ]
机构：
[1] Drexel Univ, Philadelphia, PA 19104 USA
[2] Pfizer, Predict Informat, R&d Bt Bi, Collegeville, PA USA
[3] Pfizer, Med Affairs, Collegeville, PA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.1857
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0519
引用
收藏
页码：402 / 403
页数：2
相关论文
共 6 条
[1]   Juvenile idiopathic arthritis-associated uveitis [J].
Clarke, Sarah L. N. ;
Sen, Ethan S. ;
Ramanan, Athimalaipet V. .
PEDIATRIC RHEUMATOLOGY, 2016, 14
[2]   Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry [J].
Foeldvari, Ivan ;
Becker, Ingrid ;
Horneff, Gerd .
ARTHRITIS CARE & RESEARCH, 2015, 67 (11) :1529-1535
[3]  
Petty RE, 2004, J RHEUMATOL, V31, P390
[4]  
Roshak K., COMMUNICATION
[5]   Etanercept and uveitis in patients with juvenile idiopathic arthritis [J].
Schmeling, H ;
Horneff, G .
RHEUMATOLOGY, 2005, 44 (08) :1008-1011
[6]  
Wentworth Bailey A, 2014, F1000Prime Rep, V6, P41, DOI 10.12703/P6-41
1